When do you recommend limited or targeted respiratory pathogen testing versus a full respiratory pathogen panel in a patient presenting with URI symptoms?
In other words, are there benefits to identifying URI pathogens that do not necessarily have targeted therapies (e.g., rhinovirus, non-COVID-19 Coronavirus, human metapneumovirus, etc.)?
Answer from: at Academic Institution
I think we’re asking the wrong group of people. How infectious disease physicians use respiratory pathogen panels is not the same as how emergency medicine or urgent care clinicians use them. For stewards of diagnostics, especially ID providers, the test often doesn’t change management. ...
Comments
at Cooperman Barnabas Medical Center I agree with Dr. @Weiss that RPPs are used more by...
For this question, I start with several factors in mind: how sick is the patient, where is the clinical encounter taking place (office vs inpatient hospital vs ICU), what are the patient specific risk factors that would put them at risk for more severe disease, and how does the testing impact treatm...
When the RPP came out, I, then still a molecular virologist, thought, "Wow, this test is really going to help me practice ID." I thought I could figure out who was at risk for secondary bacterial infection and, sometimes, diagnose a bacterial pathogen I could treat. I couldn't have been much more wr...
I agree with Dr. @Weiss that RPPs are used more by...